PMID- 30186483
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 1792-0981 (Print)
IS  - 1792-1015 (Electronic)
IS  - 1792-0981 (Linking)
VI  - 16
IP  - 3
DP  - 2018 Sep
TI  - Efficacy and safety of baricitinib for active rheumatoid arthritis in patients 
      with an inadequate response to conventional synthetic or biological 
      disease-modifying anti-rheumatic drugs: A meta-analysis of randomized controlled 
      trials.
PG  - 2449-2459
LID - 10.3892/etm.2018.6495 [doi]
AB  - The purpose of the present meta-analysis was to assess the efficacy and safety of 
      baricitinib for active rheumatoid arthritis (RA) in patients with an inadequate 
      response or intolerance to conventional synthetic or biological disease-modifying 
      anti-rheumatic drugs (DMARDs). A total of 7 randomized controlled trials (RCTs) 
      were included. The primary effective outcome was the RA improvement to reach an 
      American College of Rheumatology 20% (ACR20) response rate. The safety outcomes 
      were composed of clinical laboratory parameters. All patients included received 4 
      mg baricitinib once daily to treat RA for 12 or 24 weeks. The ACR20 response rate 
      in the baricitinib group was significantly higher compared with that in the 
      control group at 12 weeks [relative risk (RR), 1.77; 95% confidence interval 
      (CI), 1.62-1.94; P<0.00001] and 24 weeks (RR, 1.76; 95% CI, 1.48-2.10; 
      P<0.00001). Similarly, other effective outcome measures also exhibited 
      significant improvements in the baricitinib group compared with those in the 
      placebo group. Regarding the safety outcomes, no significant difference in 
      adverse events (AEs) was identified at 12 weeks (P=0.14), but AEs were 
      significantly higher in the baricitinib group compared with those in the control 
      group at 24 weeks (P=0.03). Most laboratory values were significantly different 
      between the baricitinib and placebo groups; however, the clinical significance of 
      these changes remains to be determined. In summary, the present meta-analysis 
      demonstrated that 4 mg baricitinib once daily was beneficial in patients with 
      active RA with an inadequate response or intolerance to conventional synthetic or 
      biological DMARDs. More high-quality RCTs are required to determine the sustained 
      efficacy and the safety of baricitinib.
FAU - Wu, Zhi-Peng
AU  - Wu ZP
AD  - Department of Orthopedics, The Second Xiangya Hospital, Central South University, 
      Changsha, Hunan 410011, P.R. China.
FAU - Zhang, Pei
AU  - Zhang P
AD  - Department of Orthopedics, Dalian Medical University, Dalian, Liaoning 116044, 
      P.R. China.
FAU - Bai, Jian-Zhong
AU  - Bai JZ
AD  - Department of Orthopedics, Dalian Medical University, Dalian, Liaoning 116044, 
      P.R. China.
FAU - Liang, Yuan
AU  - Liang Y
AD  - Department of Orthopedics, Clinical Medical College of Yangzhou University, Subei 
      People's Hospital of Jiangsu Province, Yangzhou, Jiangsu 225001, P.R. China.
FAU - He, Jin-Shan
AU  - He JS
AD  - Department of Orthopedics, Clinical Medical College of Yangzhou University, Subei 
      People's Hospital of Jiangsu Province, Yangzhou, Jiangsu 225001, P.R. China.
FAU - Wang, Jing-Cheng
AU  - Wang JC
AD  - Department of Orthopedics, The Second Xiangya Hospital, Central South University, 
      Changsha, Hunan 410011, P.R. China.
AD  - Department of Orthopedics, Dalian Medical University, Dalian, Liaoning 116044, 
      P.R. China.
AD  - Department of Orthopedics, Clinical Medical College of Yangzhou University, Subei 
      People's Hospital of Jiangsu Province, Yangzhou, Jiangsu 225001, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20180720
PL  - Greece
TA  - Exp Ther Med
JT  - Experimental and therapeutic medicine
JID - 101531947
PMC - PMC6122435
OTO - NOTNLM
OT  - Janus kinase inhibitor
OT  - baricitinib
OT  - efficacy
OT  - meta-analysis
OT  - rheumatoid arthritis
OT  - safety
EDAT- 2018/09/07 06:00
MHDA- 2018/09/07 06:01
PMCR- 2018/07/20
CRDT- 2018/09/07 06:00
PHST- 2017/10/22 00:00 [received]
PHST- 2018/06/01 00:00 [accepted]
PHST- 2018/09/07 06:00 [entrez]
PHST- 2018/09/07 06:00 [pubmed]
PHST- 2018/09/07 06:01 [medline]
PHST- 2018/07/20 00:00 [pmc-release]
AID - ETM-0-0-6495 [pii]
AID - 10.3892/etm.2018.6495 [doi]
PST - ppublish
SO  - Exp Ther Med. 2018 Sep;16(3):2449-2459. doi: 10.3892/etm.2018.6495. Epub 2018 Jul 
      20.